Literature DB >> 21304408

Cotransfection of Poly(I: C) and siRNA of IL-10 into fusions of dendritic and glioma cells enhances antitumor T helper type 1 induction in patients with glioma.

Yasuharu Akasaki1, Tetsuro Kikuchi, Masaki Irie, Yohei Yamamoto, Takao Arai, Toshihide Tanaka, Tatsuhiro Joki, Toshiaki Abe.   

Abstract

Apart from generating T-helper (Th) effector responses, dendritic cells (DCs) are capable of initiating tolerance against the inciting antigens. Therefore, successful DC-based immunotherapy against malignant tumors requires an additional strategy to activate antigen-processing DCs. We studied the antitumor immune responses conferred by fusions of DCs and glioma cells in vitro. Fusion cells (FCs) were stimulated with polyriboinosinic polyribocytidylic acid [Poly(I:C)] and/or small interference RNA (siRNA) of IL-10 (IL-10-siRNA). Increased IFN-β expression induced by Poly(I:C) transfection was accompanied by enhanced production of IL-10 and IL-12p70 in the FCs. We also found that the ability of Poly(I:C)-transfected FCs to produce IL-12p70, but not IFN-β, was preserved when endogenous IL-10 was suppressed by IL-10-siRNA. To analyze the antigen-presenting function further, DCs, glioma cells, and peripheral lymphocytes were established from patients newly diagnosed with glioma. In this experiment, peripheral lymphocytes were stimulated with autologous FCs and restimulated with autologous glioma cells. CD4T cells isolated from the stimulated lymphocytes were subjected to the ELISPOT and WST-1 assays, which revealed that the IL-10-siRNA/Poly(I:C)-cotransfected FCs elicit an efficient tumor-specific Th1 response. These findings support the relevance of using Poly(I:C) and IL-10-siRNA in clinical immunotherapy protocols with an FC-based vaccine for patients with malignant glioma as a means of promoting Th1-induced tumor antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304408     DOI: 10.1097/CJI.0b013e3181e5c278

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  6 in total

1.  New therapeutic approaches for malignant glioma: in search of the Rosetta stone.

Authors:  Brenda Auffinger; Bart Thaci; Pragati Nigam; Esther Rincon; Yu Cheng; Maciej S Lesniak
Journal:  F1000 Med Rep       Date:  2012-09-05

Review 2.  Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.

Authors:  Fabian Benencia; Leslee Sprague; John McGinty; Michelle Pate; Maria Muccioli
Journal:  J Biomed Biotechnol       Date:  2012-03-15

Review 3.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

Review 4.  Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.

Authors:  Shigeo Koido
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 5.  Latest development on RNA-based drugs and vaccines.

Authors:  Kenneth Lundstrom
Journal:  Future Sci OA       Date:  2018-05-04

6.  Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain.

Authors:  Sergiy V Kushchayev; Tejas Sankar; Laura L Eggink; Yevgeniya S Kushchayeva; Philip C Wiener; J Kenneth Hoober; Jennifer Eschbacher; Ruolan Liu; Fu-Dong Shi; Mohammed G Abdelwahab; Adrienne C Scheck; Mark C Preul
Journal:  Cancer Manag Res       Date:  2012-09-17       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.